• Users Online: 74
  • Print this page
  • Email this page
DRUG PROFILE
Year : 2013  |  Volume : 4  |  Issue : 1  |  Page : 54-57

Topical rapamycin (sirolimus) for facial angiofibromas


Department of Skin & VD, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital, Sewagram, Wardha, Maharashtra, India

Correspondence Address:
Bhushan Madke
Department of Skin & VD, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital, Sewagram, Wardha, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-5178.105488

Rights and Permissions

Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at molecular level. Rapamycin (sirolimus) is routinely incorporated in drug-eluting stents used for cardiac angioplasty. In recent years, rapamycin was found to be efficacious in managing the symptom complex of tuberous sclerosis, i.e. renal angiomyolipoma, giant cell astrocytoma and pulmonary lymphangiomyomatosis. Various investigators have also proved that topically applied rapamycin causes regression of facial angiofibromas, giving better cosmetic results.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed8065    
    Printed108    
    Emailed5    
    PDF Downloaded929    
    Comments [Add]    
    Cited by others 10    

Recommend this journal